Severe Asthma in School-Age Children: An Updated Appraisal on Biological Options and Challenges in This Age Group DOI Creative Commons
Cristiana Indolfi, Angela Klain,

Marina Capuano

et al.

Children, Journal Year: 2025, Volume and Issue: 12(2), P. 167 - 167

Published: Jan. 29, 2025

This review examines the growing role of biological therapies in managing severe asthma children aged 6–11 years. Severe asthma, characterized by persistent symptoms and frequent exacerbations, presents significant challenges pediatric care. Biologic treatments, including mepolizumab, omalizumab, dupilumab, provide targeted interventions for patients with high eosinophilic inflammation or allergic (T2-high asthma). Alongside their therapeutic benefits, evaluates safety profiles these biologics, highlighting potential side effects necessity monitoring during long-term use. Cost considerations treatment adherence also emerge as important that need to be addressed clinical practice. Additionally, emphasizes identifying who would derive most benefit from biologic therapies, advocating development biomarkers aid decisions. Emerging such tezepelumab, are introduced promising alternatives target upstream inflammatory pathways, offering hope treating T2-low forms, which currently lack effective options children.

Language: Английский

Update on the diagnosis of severe asthma in children and adolescents DOI Creative Commons

A. Agustí Vidal

Published: Jan. 10, 2025

Severe pediatric asthma is a very challenging type of for both physicians and patients. Precision medicine in severe has undergone important developments recent years. This therapeutic approach requires an adequate diagnosis clinical phenotyping patients useful predicting the prognosis response to treatment this patient. article summarizes scientific information last five years asthma, focusing on topics such as genetic markers, biomarkers, lung function, radiological techniques, bronchoscopy.

Language: Английский

Citations

1
Severe Asthma in School-Age Children: An Updated Appraisal on Biological Options and Challenges in This Age Group DOI Creative Commons
Cristiana Indolfi, Angela Klain,

Marina Capuano

et al.

Children, Journal Year: 2025, Volume and Issue: 12(2), P. 167 - 167

Published: Jan. 29, 2025

This review examines the growing role of biological therapies in managing severe asthma children aged 6–11 years. Severe asthma, characterized by persistent symptoms and frequent exacerbations, presents significant challenges pediatric care. Biologic treatments, including mepolizumab, omalizumab, dupilumab, provide targeted interventions for patients with high eosinophilic inflammation or allergic (T2-high asthma). Alongside their therapeutic benefits, evaluates safety profiles these biologics, highlighting potential side effects necessity monitoring during long-term use. Cost considerations treatment adherence also emerge as important that need to be addressed clinical practice. Additionally, emphasizes identifying who would derive most benefit from biologic therapies, advocating development biomarkers aid decisions. Emerging such tezepelumab, are introduced promising alternatives target upstream inflammatory pathways, offering hope treating T2-low forms, which currently lack effective options children.

Language: Английский

Citations

1